Jade Biosciences, Inc. JBIO
Regular-session close
After hours · Nov 20, 4:01 PM ET
- YTD
- -0.78%
- 1 year
- +33.36%
- Market cap
- 1.06B
- EPS (ttm)
- -1.83
- Shares out
- 69.19M
- Forward P/E
- -6.78
- YTD return
- -0.78%
- 1-year return
- +33.36%
- 50-day average
- 15.00
- 200-day average
- 18.21
- Enterprise value
- 567.02M
- Volume
- 1.02M
- Avg volume
- 910.19K
- Open
- 15.00
- Previous close
- 15.06
- Day's range
- 15.00 – 15.53
- 52-week range
- 11.48 – 26.85
- Analysts
- Strong Buy
- Price target
- 49.38 (+222.5%)
- Earnings date
- Mar 5, 2027
Key statistics
- Price / book
- 2.25
- Total cash
- 475.71M
- Total debt
- 733.00K
- Short % of float
- 18.71%
Fundamental scorecard
5 of 25 checks passed on JBIO’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 40.00
- Target (mean)
- 49.38
- Target (high)
- 77.00
- Strong buy0
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 5, 2027
Expected Mar 5, 2027. Consensus EPS estimate -0.4134.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 5, 2027 | Dec 30, 2026 | -0.64 | — | — | — |
| Nov 13, 2026 | Sep 30, 2026 | -0.73388 | -0.42 | +0.31 | +42.77% |
| Aug 10, 2026 | Jun 30, 2026 | -0.63642 | -0.76 | -0.12 | -19.42% |
| May 7, 2026 | Mar 31, 2026 | -0.52 | -0.57 | -0.05 | -9.62% |
| Mar 6, 2026 | Dec 31, 2025 | -0.45 | -0.45 | 0.00 | 0.00% |
| Nov 14, 2025 | Sep 30, 2025 | -0.57 | -0.48 | +0.09 | +15.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 16, 2026 | Guggenheim | main | Buy | Buy |
| Oct 27, 2026 | BTIG | reit | Buy | Buy |
| Oct 1, 2026 | Wedbush | reit | Outperform | Outperform |
| Oct 1, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 11, 2026 | Wedbush | main | Outperform | Outperform |
| Aug 10, 2026 | BTIG | main | Buy | Buy |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- jadebiosciences.com
News
Jade Biosciences, Inc. (JBIO) Presents at UBS Global Biopharma Conference 2026 Transcript Guggenheim Maintains Buy on Jade Biosciences, Lowers Price Target to $41
Jade Biosciences Q3 EPS $(0.42) Beats $(0.71) Estimate
12 Health Care Stocks Moving In Tuesday's Pre-Market Session BTIG Reiterates Buy on Jade Biosciences, Maintains $77 Price Target
Your note
Sign in to keep a note on JBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BALTA ELIZABETH | Officer | Stock Award(Grant) | Feb 11, 2026 | 28,125 |
| DAHMS BRADFORD D | Chief Financial Officer | Stock Award(Grant) | Feb 11, 2026 | 37,813 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Oct 5, 2025 | 0 |
| FROHLICH TOM | Chief Executive Officer | Stock Award(Grant) | Feb 11, 2026 | 86,331 |
| KING ANDREW JAMES | Officer | Stock Award(Grant) | Feb 11, 2026 | 386,113 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.18% | 9,810,088 | 150.19M | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 10.11% | 6,991,676 | 107.04M | Sep 29, 2026 |
| Paradigm Biocapital Advisors LP | 8.75% | 6,053,268 | 92.68M | Sep 29, 2026 |
| Fairmount Funds Management LLC | 6.58% | 4,553,494 | 69.71M | Sep 29, 2026 |
| Bellevue Group AG | 6.21% | 4,293,937 | 65.74M | Sep 29, 2026 |
| Franklin Templeton, Inc. | 5.50% | 3,807,236 | 58.29M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.48% | 1,714,640 | 26.25M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.46% | 1,699,343 | 26.02M | Jun 29, 2026 |
| Franklin Value Investors Trust-FRANKLIN SMALL CAP VALUE FUND | 2.04% | 1,412,559 | 21.63M | Jul 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.72% | 1,191,884 | 18.25M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.49% | 1,032,642 | 15.81M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.45% | 1,000,000 | 15.31M | Sep 29, 2026 |
